DYRK1A and trisomy 21: Therefore, DYRK1A inhibition may present a therapeutic intervention for Trisomy 21, with the potential to manage and/or reverse adverse neurological symptoms, including the increased risk of neurofibrillary degeneration and the development of dementia [116, 276, 277].